ReviewCancer control : journal of the Moffitt Cancer Center
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Gene, genetics and genetic medicines in gastroenterology: Current status and its future.World journal of gastroenterology · 2026Review
- Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.Oncology and therapy · 2025Review
- Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports.The oncologist · 2025Article
- Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17-18 October 2024.Current oncology (Toronto, Ont.) · 2025Article
- Article
- BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications.International journal of molecular sciences · 2025Review
- Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy forJCO precision oncology · 2025Article
- Digestive cancers: mechanisms, therapeutics and management.Signal transduction and targeted therapy · 2025Review
- Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets.ESMO open · 2024Review
- Frequency of Common and UncommonCancers · 2024Article
- New trends in diagnosis and management of gallbladder carcinoma.World journal of gastrointestinal oncology · 2024Review
- How to incorporate new agents into precise medicine for cholangiocarcinoma?American journal of cancer research · 2024Review
- Perioperative and palliative systemic treatments for biliary tract cancer.Therapeutic advances in medical oncology · 2024Review
- Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer.World journal of gastrointestinal oncology · 2023Review
- Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.Diagnostics (Basel, Switzerland) · 2023Article
- Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.Cancers · 2023Review
- Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes.Open medicine (Warsaw, Poland) · 2023Article
- Review
- Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). METHODS &
resultsIn the current review, we will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials.
conclusionsAlthough the extended use of molecular profiling has paved the way toward a new era in BTC management, targeted therapies are limited to iCCA so far, and the prognosis of patients with metastatic disease has substantially not changed in the last decade. In this discouraging scenario, BRAF inhibition is currently emerging as a novel treatment option in patients harboring BRAF mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.